Investigational drug · Phase 2
MTX101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Migraine.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "MTX101"
First trial start
2025
Feb 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MTX101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Migraine
Approved drugs for the same conditions: Migraine · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MTX101" as an intervention, largest first.
Mozart Therapeutics Australia Pty LtdIndustry
NCT06324604 · 96 participants (planned) · Start Jun 13, 2024 · Primary completion Mar 31, 2027
Drug: Placebo; MTX-101 · For: Healthy Volunteers; Type 1 Diabetes
Sites: Heidelberg, Australia; Melbourne, Australia; Fitzroy, Australia
Manistee TherapeuticsIndustry
NCT06728553 · 78 participants · Start Feb 24, 2025 · Primary completion Jun 27, 2025
Drug: MTX101; Placebo · For: Migraine
Sites: La Jolla, California; Santa Monica, California; Miami, Florida · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases.
Gardell JL, Maurer ME, Childs MM, et al. · Front Immunol 2024
Also in development for Migraine
- AXS-07meloxicam-rizatriptanPhase 31 trial
Axsome Therapeutics, Inc. · Migraine
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BHV-2100Phase 21 trial
Biohaven Therapeutics Ltd. · Migraine
- MEDI0618Phase 21 trial
AbbVie · Migraine
- PRT-064040Phase 21 trial
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Migraine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.